190 related articles for article (PubMed ID: 23857864)
21. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
22. Denosumab: A Review in Postmenopausal Osteoporosis.
Deeks ED
Drugs Aging; 2018 Feb; 35(2):163-173. PubMed ID: 29435849
[TBL] [Abstract][Full Text] [Related]
23. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
24. Denosumab for postmenopausal osteoporosis?
Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
[TBL] [Abstract][Full Text] [Related]
25. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.
Neuprez A; Coste S; Rompen E; Crielaard JM; Reginster JY
Osteoporos Int; 2014 Jan; 25(1):393-5. PubMed ID: 23835864
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
Chandran T; Venkatachalam I
Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
[TBL] [Abstract][Full Text] [Related]
27. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
28. [Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis].
Ershova OB; Lesniak OM; Belova KIu; Nazarova AV; Manovitskaia AV; Musaeva TM; Musraev RM; Nurlygaianov RZ; Rozhinskaia LIa; Skripnikova IA; Toroptsova NV
Ter Arkh; 2014; 86(10):60-4. PubMed ID: 25509894
[TBL] [Abstract][Full Text] [Related]
29. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
30. Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed.
Ferrari S; Lewiecki EM; Butler PW; Kendler DL; Napoli N; Huang S; Crittenden DB; Pannacciulli N; Siris E; Binkley N
Bone; 2020 May; 134():115287. PubMed ID: 32092479
[TBL] [Abstract][Full Text] [Related]
31. Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Muschitz C; Fahrleitner-Pammer A; Huber J; Preisinger E; Kudlacek S; Resch H
Wien Med Wochenschr; 2012 Sep; 162(17-18):374-9. PubMed ID: 22688622
[TBL] [Abstract][Full Text] [Related]
32. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
33. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
Bridgeman MB; Pathak R
Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
[TBL] [Abstract][Full Text] [Related]
34. Denosumab (prolia) for postmenopausal osteoporosis.
Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
[No Abstract] [Full Text] [Related]
35. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years.
Watts NB; Grbic JT; Binkley N; Papapoulos S; Butler PW; Yin X; Tierney A; Wagman RB; McClung M
J Clin Endocrinol Metab; 2019 Jun; 104(6):2443-2452. PubMed ID: 30759221
[TBL] [Abstract][Full Text] [Related]
36. Antiresorptives: Safety Concerns-Clinical Perspective.
Brown JP
Toxicol Pathol; 2017 Oct; 45(7):859-863. PubMed ID: 29065818
[TBL] [Abstract][Full Text] [Related]
37. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.
Wu J; Zhang Q; Yan G; Jin X
J Orthop Surg Res; 2018 Aug; 13(1):194. PubMed ID: 30071889
[TBL] [Abstract][Full Text] [Related]
38. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
39. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
[TBL] [Abstract][Full Text] [Related]
40. Denosumab: recent update in postmenopausal osteoporosis.
Silva I; Branco JC
Acta Reumatol Port; 2012; 37(4):302-13. PubMed ID: 24126422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]